Belite Bio (BLTE) Operating Expenses (2022 - 2026)

Belite Bio's Operating Expenses history runs 5 years deep, the most recent figure standing at $32.7 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 110.63% year-over-year to $32.7 million in Q1 2026; TTM through Mar 2026 was $68.7 billion, a 116.91% increase from a year earlier, with the FY2025 full-year figure at $84.2 million, up 110.54% from the prior year.
• Operating Expenses eased to $32.7 million in Q1 2026 per BLTE's latest filing, from $28.1 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $28.1 billion in Q4 2025 and bottomed at $6.7 million in Q4 2022.
• The 5-year median for Operating Expenses is $6.9 billion (2023), against an average of $8.0 billion.
• Across the five-year window, Operating Expenses surged 164630.41% in 2024 and sank 99.81% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $6.7 million in 2022, then increased by 3.48% to $7.0 million in 2023, then jumped by 164630.41% to $11.5 billion in 2024, then jumped by 145.06% to $28.1 billion in 2025, then tumbled by 99.88% to $32.7 million in 2026.
• Per Business Quant, the three latest BLTE Operating Expenses figures stand at $32.7 million (Q1 2026), $28.1 billion (Q4 2025), and $23.0 billion (Q3 2025).